Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Other Operating Expenses (2016 - 2025)

Standard Biotools (LAB) has disclosed Other Operating Expenses for 16 consecutive years, with $13.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses rose 148.34% to $13.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$32.5 million, a 82.87% increase, with the full-year FY2024 number at -$168.7 million, down 2.66% from a year prior.
  • Other Operating Expenses was $13.0 million for Q3 2025 at Standard Biotools, up from -$12.6 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $18.0 million in Q4 2021 to a low of -$57.7 million in Q2 2024.
  • A 5-year average of -$14.2 million and a median of -$12.6 million in 2025 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: plummeted 2763900.0% in 2023, then skyrocketed 148.34% in 2025.
  • Standard Biotools' Other Operating Expenses stood at $18.0 million in 2021, then crashed by 100.01% to -$2000.0 in 2022, then tumbled by 2763900.0% to -$55.3 million in 2023, then soared by 38.41% to -$34.0 million in 2024, then surged by 138.21% to $13.0 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Other Operating Expenses are $13.0 million (Q3 2025), -$12.6 million (Q2 2025), and $1.1 million (Q1 2025).